Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis

BACKGROUND: Continuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer. As a protracted low-dose infusion, 5FU is antiangiogenic, and has synergy with bevacizumab. As shown in the treatment of br...

Descripción completa

Detalles Bibliográficos
Autores principales: Isacoff, William H., Reber, Howard A., Bedford, Rudolph, Hoos, William, Rahib, Lola, Upfill-Brown, Alexander, Donahue, Timothy, Hines, O. Joe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096752/
https://www.ncbi.nlm.nih.gov/pubmed/29882102
http://dx.doi.org/10.1007/s11523-018-0572-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096752/
https://www.ncbi.nlm.nih.gov/pubmed/29882102
http://dx.doi.org/10.1007/s11523-018-0572-3

Ejemplares similares